Dr. Zhi Chen is an Associate Scientific Director in the Sterile Product Development department at Bristol Myers Squibb. He leads a team of formulation and analytical scientists responsible for developing strategies to support formulation and process development for a wide range of drug product modalities, including antibodies, fusion proteins, antibody-drug conjugates (ADCs), oligonucleotides, lipid nanoparticles (LNPs), and long-acting injectable small molecules (LAIs). Dr. Chen has made significant contributions to numerous IND and BLA filings, playing a pivotal role in advancing drug products through various stages of development. Prior to joining BMS, Dr. Chen held key positions at Merck, Novartis, and legacy Schering-Plough. He was instrumental in the commercialization of several marketed products, including Keytruda®, Opdivo®, Opdualag™, and, most recently, Opdivo Qvantig™.